Early Neuropsychiatric and Cutaneous Manifestations as Sentinel Signs of Systemic Disease
DOI:
https://doi.org/10.64784/297Keywords:
systemic diseases, neuropsychiatric manifestations, cutaneous manifestations, early diagnosis, sentinel signs, systemic lupus erythematosus, Sjögren syndrome, Behçet disease, sarcoidosis, antiphospholipid syndrome, systemic vasculitis, peripheral neuropathy, autoimmune diseases, vascular manifestationsAbstract
Systemic diseases may present with cutaneous, neurological, or psychiatric manifestations before the classical diagnostic phenotype becomes fully established, creating a clinically relevant prediagnostic window. This study analyzed the main neuropsychiatric and cutaneous manifestations associated with systemic lupus erythematosus, Sjögren syndrome, Behçet disease, sarcoidosis, antiphospholipid syndrome, and systemic vasculitis, with emphasis on their temporal relationship with definitive diagnosis and their potential value as early warning signs. An integrative literature review based on the scientific method was conducted using evidence obtained from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar. The analysis considered the type of systemic disease, cutaneous findings, neurological or psychiatric manifestations, predominant pathophysiological mechanisms, and timing in relation to diagnosis. The reviewed evidence showed that systemic lupus erythematosus presented the broadest clinical heterogeneity, while neurological manifestations in Sjögren syndrome may precede classical glandular symptoms. Recurrent mucosal ulceration was particularly relevant in Behçet disease, granulomatous skin lesions provided diagnostic support in sarcoidosis, and vascular skin abnormalities were associated with neurological ischemic events in antiphospholipid syndrome and systemic vasculitis. The most recurrent mechanisms included autoimmune-inflammatory, vascular-thrombotic, vasculitic, and granulomatous pathways. Clinically relevant combinations included purpura with peripheral neuropathy, livedoid skin changes with cerebrovascular events, recurrent mucosal ulceration with neurological inflammation, photosensitive lesions with neuropsychiatric abnormalities, and granulomatous skin disease with neurological involvement. These findings indicate that isolated manifestations have limited specificity, whereas coherent multisystem patterns may increase suspicion of an underlying systemic disorder. Integrating dermatological and neuropsychiatric findings into multidisciplinary clinical assessment may contribute to earlier diagnostic recognition and reduce delays before significant organ involvement develops.
References
[1] C. H. Siegel and L. R. Sammaritano, “Systemic lupus erythematosus: A review,” JAMA, vol. 331, no. 17, pp. 1480–1491, 2024, doi: 10.1001/jama.2024.2315.
[2] C. Stull, G. Sprow, and V. P. Werth, “Cutaneous involvement in systemic lupus erythematosus: A review for the rheumatologist,” J. Rheumatol., vol. 50, no. 1, pp. 27–35, 2023, doi: 10.3899/jrheum.220089.
[3] P. Curtiss, A. M. Walker, and B. F. Chong, “A systematic review of the progression of cutaneous lupus to systemic lupus erythematosus,” Front. Immunol., vol. 13, Art. no. 866319, 2022, doi: 10.3389/fimmu.2022.866319.
[4] I. T. Wieczorek, K. J. Propert, J. Okawa, and V. P. Werth, “Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus,” JAMA Dermatol., vol. 150, no. 3, pp. 291–296, 2014, doi: 10.1001/jamadermatol.2013.9026.
[5] A. L. Meier et al., “Neuro-psychiatric manifestations in patients with systemic lupus erythematosus: A systematic review and results from the Swiss lupus cohort study,” Lupus, vol. 30, no. 10, pp. 1565–1576, 2021, doi: 10.1177/09612033211025636.
[6] H. Jeltsch-David and S. Muller, “Neuropsychiatric systemic lupus erythematosus: Pathogenesis and biomarkers,” Nat. Rev. Neurol., vol. 10, no. 10, pp. 579–596, 2014, doi: 10.1038/nrneurol.2014.148.
[7] K. Nakamura et al., “Guidelines for the treatment of skin and mucosal lesions in Behçet’s disease: A secondary publication,” J. Dermatol., vol. 47, no. 3, pp. 223–235, 2020, doi: 10.1111/1346-8138.15207.
[8] S. Kalra et al., “Diagnosis and management of Neuro-Behçet’s disease: International consensus recommendations,” J. Neurol., vol. 261, no. 9, pp. 1662–1676, 2014, doi: 10.1007/s00415-013-7209-3.
[9] D. P. Kidd, “Neurological involvement by Behçet’s syndrome: Clinical features, diagnosis, treatment and outcome,” Pract. Neurol., vol. 23, no. 5, pp. 386–400, 2023, doi: 10.1136/pn-2023-003875.
[10] M. J. Bradshaw, S. Pawate, L. L. Koth, T. A. Cho, and J. M. Gelfand, “Neurosarcoidosis: Pathophysiology, diagnosis, and treatment,” Neurol. Neuroimmunol. Neuroinflamm., vol. 8, no. 6, Art. no. e1084, 2021, doi: 10.1212/NXI.0000000000001084.
[11] J. Koneti, S. P. Cherukuri, S. Gadde, R. Kalluru, R. Chikatimalla, and T. Dasaradhan, “Sarcoidosis and its dermatological manifestations: A narrative review,” Cureus, vol. 14, no. 8, Art. no. e28053, 2022, doi: 10.7759/cureus.28053.
[12] R. T. Ibitoye, A. Wilkins, and N. J. Scolding, “Neurosarcoidosis: A clinical approach to diagnosis and management,” J. Neurol., vol. 264, no. 5, pp. 1023–1028, 2017, doi: 10.1007/s00415-016-8336-4.
[13] P. Jhorar, K. Torre, and J. Lu, “Cutaneous features and diagnosis of primary Sjögren syndrome: An update and review,” J. Am. Acad. Dermatol., vol. 79, no. 4, pp. 736–745, 2018, doi: 10.1016/j.jaad.2018.05.021.
[14] A. Popescu, J. Hickernell, A. Paulson, and Z. Aouhab, “Neurological and psychiatric clinical manifestations of Sjögren syndrome,” Curr. Neurol. Neurosci. Rep., vol. 24, no. 8, pp. 293–301, 2024, doi: 10.1007/s11910-024-01352-z.
[15] F. Teixeira, I. Moreira, A. M. Silva, C. Vasconcelos, F. Farinha, and E. Santos, “Neurological involvement in primary Sjögren syndrome,” Acta Reumatol. Port., vol. 38, no. 1, pp. 29–36, 2013.
[16] E. Generali, A. Costanzo, C. Mainetti, and C. Selmi, “Cutaneous and mucosal manifestations of Sjögren’s syndrome,” Clin. Rev. Allergy Immunol., vol. 53, no. 3, pp. 357–370, 2017, doi: 10.1007/s12016-017-8639-y.
[17] M. Leal Rato, M. Bandeira, V. C. Romão, and D. Aguiar de Sousa, “Neurologic manifestations of the antiphospholipid syndrome—An update,” Curr. Neurol. Neurosci. Rep., vol. 21, no. 8, Art. no. 41, 2021, doi: 10.1007/s11910-021-01124-z.
[18] M. Gomez-Flores et al., “Cutaneous manifestations of antiphospholipid syndrome,” Lupus, vol. 30, no. 4, pp. 541–548, 2021, doi: 10.1177/0961203321990100.
[19] R. G. Micheletti et al., “Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis,” Arthritis Rheumatol., vol. 72, no. 10, pp. 1741–1747, 2020, doi: 10.1002/art.41310.
[20] S. Zhang, D. Yuan, and G. Tan, “Neurological involvement in primary systemic vasculitis,” Front. Neurol., vol. 10, Art. no. 430, 2019, doi: 10.3389/fneur.2019.00430.
